Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

APPY 1.80 +0.09 (5.26%)
price chart
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Venaxis Files Response to FDA's Request for Additional Information  SYS-CON Media (press release)
Related articles »  
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  PR Newswire (press release)
Related articles »  
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session
Venaxis, Inc. was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Related articles »  
Venaxis Inc (APPY) news: What Every Investor Needs To Know About Venaxis, Inc.
Computed tomography imaging is used to diagnose approximately 35% of these cases, but comes with a heavy radioactive price tag. Accuracy of computer tomography imaging is measured at 93-98%.
Venaxis: Latest Clinical Data Reveals Huge Market Potential (APPY)
Venaxis Inc. recently reported detailed data of the clinical pathways undertaken by the pediatric patients enrolled in their pivotal trial.
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies ...
CASTLE ROCK, Colo., Nov. 13, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children ...
Related articles »  
Venaxis Inc (APPY) news: Venaxis's Pivotal Data Due In March
(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap.
Related articles »  
Venaxis Inc (APPY): Venaxis: The Hidden Gem With A 'Feel-Good' Investment ...
Venaxis recently, on 7/29, penetrated its previous resistance at $1.40 by more than 8% and established new support at $1.40 (Volume was 270% higher at 3.0M than the average 1.1M for the day).
Related articles »  
Venaxis Inc (APPY) news: Venaxis expects APPY1 approval following positive ...
Venaxis' (APPY) APPY1 Test for identifying patients who are at low risk of appendicitis performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study.
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Venaxis (NASDAQ:APPY) is a diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test.